NASDAQ: CASI | 中文 | Contact Us

Thiotepa

The Company acquired exclusive China rights for the development and distribution of a novel formulation of Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting.

Clinical Development Status

CASI intends to advance the development, import drug registration, and market approval of this product in China.

About Us

CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.

Learn More